As Sanofi Exits Diabetes R&D, Meaning Of ‘Diabetes R&D’ Blurs
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.
You may also be interested in...
And how in contrast, Novo Nordisk is launching its oral GLP-1 agonist for diabetes at a price that may set up 'business as usual' tensions with pharmacy benefit managers and payers.
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
Expanded indication for type 1 diabetes seems out of reach for the moment, but if Boehringer conducts a larger and lengthier trial, it could eventually persuade members of the Endocrinologic and Metabolic Drugs Advisory Committee who voted 14-2 against supplemental approval of empagliflozin for the proposed 2.5mg dose.